Arecor Therapeutics (LSE:AREC) Total Tax Payable: £0.08 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:AREC Arecor Therapeutics PLC LSE:AREC
37 GF Score
Price £0.61
GF Value £0.44
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arecor Therapeutics Total Tax Payable?

Arecor Therapeutics LSE:AREC -3.94% 37 Total Tax Payable is £0.08 Mil as of Dec. 2025. GuruFocus rates LSE:AREC with a GF Score™ of 37/100 and a GF Value™ of £0.44 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Arecor Therapeutics's Total Tax Payable for the quarter that ended in Dec. 2025 was £0.08 Mil.

Arecor Therapeutics's quarterly Total Tax Payable declined from Dec. 2024 (£0.09 Mil) to Jun. 2025 (£0.00 Mil) but then increased from Jun. 2025 (£0.00 Mil) to Dec. 2025 (£0.08 Mil).

Arecor Therapeutics's annual Total Tax Payable declined from Dec. 2023 (£0.10 Mil) to Dec. 2024 (£0.09 Mil) and declined from Dec. 2024 (£0.09 Mil) to Dec. 2025 (£0.08 Mil).

Arecor Therapeutics Total Tax Payable Related Terms

Arecor Therapeutics Total Tax Payable Historical Data

* Premium members only.

The historical data trend for Arecor Therapeutics's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arecor Therapeutics Total Tax Payable Chart

Arecor Therapeutics Annual Data
Trend May17 May18 May19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Tax Payable
Get a 7-Day Free Trial Premium Member Only 0.09 0.12 0.10 0.09 0.08

Arecor Therapeutics Semi-Annual Data
May17 May18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.16 0.09 0.00 0.08
LSE:AREC
37GF Score
Arecor Therapeutics PLC LSE:AREC
Total Tax Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arecor Therapeutics Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Frequently Asked Questions Learn more about Total Tax Payable →
What does a Total Tax Payable of £0.08 Mil mean?
Arecor Therapeutics (LSE:AREC) has a Total Tax Payable of £0.08 Mil as of Dec. 2025. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Arecor Therapeutics and its competitors.
Is Arecor Therapeutics' Total Tax Payable too high?
Arecor Therapeutics' current Total Tax Payable is £0.08 Mil. Overall, Arecor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' Total Tax Payable compare to VRTX and REGN?
Arecor Therapeutics' Total Tax Payable of £0.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Tax Payable for a Biotechnology company?
A good Total Tax Payable depends on the Biotechnology industry context. However, Total Tax Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Tax Payable mean?
A high Total Tax Payable can signal that a stock is expensive relative to its fundamentals. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Arecor Therapeutics and its competitors. Arecor Therapeutics's current Total Tax Payable is £0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Arecor Therapeutics (LSE:AREC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.44, compared to a current price of £0.61 — trading 38.6% above its estimated fair value. The current Total Tax Payable is £0.08 Mil. Arecor Therapeutics' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Tax Payable calculated?
Total Tax Payable is calculated from a company's financial statements. For Arecor Therapeutics (LSE:AREC), the current Total Tax Payable is £0.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arecor Therapeutics (LSE:AREC) Overvalued in 2026?

Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued. The current stock price of £0.61 is trading 38.6% above its estimated GF Value™ of £0.44. GuruFocus considers Arecor Therapeutics to be Significantly Overvalued.

Key valuation signals for LSE:AREC:

  • Total Tax Payable: £0.08 Mil
  • GF Value™: £0.44 vs. price of £0.61 (38.6% above fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the LSE:AREC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arecor Therapeutics Business Description

Other Exchanges 6UI:Germany
Address Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score

Get the complete analysis for LSE:AREC

Total Tax Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.61
Price
£0.44
GF Value